Other substances

repRNA-CoV2S

COVID-19 candidate vaccine

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Vaccine

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
1
 AI-suggested references
0
 Clinical trials

General information

repRNA-CoV2S is a stable and highly immunogenic COVID-19 vaccine candidate comprised of an RNA replicon formulated with a novel Lipid InOrganic Nanoparticle (LION) designed to enhance vaccine stability, delivery, and immunogenicity. 

 

Supporting references

Link Tested on Impact factor Notes Publication date
Single-dose replicating RNA vaccine induces neutralizing antibodies against SARS-CoV-2 in nonhuman primates
RNA Preprint 		pigtail macaques May/28/2020

AI-suggested references

Link Publication date
An alphavirus-derived replicon RNA vaccine induces SARS-CoV-2 neutralizing antibody and T cell responses in mice and nonhuman primates
Jun/18/2021
Export (.csv)